THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Usman Baber to Percutaneous Coronary Intervention

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Percutaneous Coronary Intervention.
Usman Baber
Connection Strength
34.958
Percutaneous Coronary Intervention
  1. Stent Failure After Percutaneous Coronary Intervention in Diabetes?Mellitus: Does Glycemic Control Matter? J Am Coll Cardiol. 2024 Jul 16; 84(3):273-275.
    View in: PubMed
    Score: 0.692
  2. Inflammatory Potential and Risk?Prediction After PCI in High?Bleeding?Risk?Patients. JACC Cardiovasc Interv. 2024 Feb 12; 17(3):356-358.
    View in: PubMed
    Score: 0.672
  3. Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
    View in: PubMed
    Score: 0.667
  4. Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done. JACC Cardiovasc Interv. 2023 01 09; 16(1):47-49.
    View in: PubMed
    Score: 0.623
  5. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
    View in: PubMed
    Score: 0.598
  6. The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how? Rev Esp Cardiol (Engl Ed). 2022 Feb; 75(2):115-118.
    View in: PubMed
    Score: 0.572
  7. Hemoglobin A1c and Cardiovascular Outcomes Following Percutaneous Coronary Intervention: Insights From a Large Single-Center Registry. JACC Cardiovasc Interv. 2021 02 22; 14(4):388-397.
    View in: PubMed
    Score: 0.547
  8. Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? EuroIntervention. 2020 Oct 23; 16(8):620-622.
    View in: PubMed
    Score: 0.534
  9. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
    View in: PubMed
    Score: 0.532
  10. Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? JACC Cardiovasc Interv. 2020 10 12; 13(19):2263-2265.
    View in: PubMed
    Score: 0.530
  11. Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. Catheter Cardiovasc Interv. 2021 01 01; 97(1):63-71.
    View in: PubMed
    Score: 0.521
  12. Ticagrelor with or without Aspirin after PCI. Reply. N Engl J Med. 2020 03 12; 382(11):1076-1077.
    View in: PubMed
    Score: 0.512
  13. Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? J Am Coll Cardiol. 2019 11 05; 74(18):2235-2237.
    View in: PubMed
    Score: 0.500
  14. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.488
  15. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.471
  16. The Challenge of Diabetes Mellitus in the Contemporary Percutaneous Coronary Intervention Era: Are We Making Progress? JACC Cardiovasc Interv. 2018 12 24; 11(24):2477-2479.
    View in: PubMed
    Score: 0.470
  17. Left Main PCI With DES Versus CABG: Cautionary Note or Cause for Concern? J Am Coll Cardiol. 2018 12 11; 72(23 Pt A):2823-2825.
    View in: PubMed
    Score: 0.469
  18. Defining PCI complexity in the contemporary DES era: Clarity or confusion? Int J Cardiol. 2018 10 01; 268:94-95.
    View in: PubMed
    Score: 0.463
  19. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.445
  20. Predicting risk for bleeding after PCI: Another step in the right direction but work remains. Int J Cardiol. 2018 03 01; 254:45-46.
    View in: PubMed
    Score: 0.442
  21. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.427
  22. Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
    View in: PubMed
    Score: 0.423
  23. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J. 2017 Jun; 188:73-81.
    View in: PubMed
    Score: 0.414
  24. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.403
  25. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.401
  26. Predicting Risk of Ischemic or Bleeding Events After Percutaneous Coronary Intervention. JAMA Cardiol. 2016 09 01; 1(6):731-2.
    View in: PubMed
    Score: 0.401
  27. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.397
  28. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.390
  29. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.383
  30. The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and Thrombosis. J Am Coll Cardiol. 2015 Sep 01; 66(9):1046-9.
    View in: PubMed
    Score: 0.374
  31. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015 Jun; 8(6):e001683.
    View in: PubMed
    Score: 0.367
  32. DAPT duration after DES: what is the "mandatory" duration? J Am Coll Cardiol. 2015 Mar 24; 65(11):1103-6.
    View in: PubMed
    Score: 0.363
  33. Coronary artery revascularization in chronic kidney disease: time for a randomized trial. Circ Cardiovasc Interv. 2015 Jan; 8(1).
    View in: PubMed
    Score: 0.357
  34. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013 Jul; 110(1):118-23.
    View in: PubMed
    Score: 0.319
  35. Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial. EuroIntervention. 2025 May 16; 21(10):550-559.
    View in: PubMed
    Score: 0.183
  36. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024 Sep 07; 404(10456):937-948.
    View in: PubMed
    Score: 0.174
  37. Mortality After Procedural or Spontaneous Myocardial Infarction. J Am Coll Cardiol. 2024 Jul 30; 84(5):467-477.
    View in: PubMed
    Score: 0.173
  38. Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
    View in: PubMed
    Score: 0.168
  39. Prognostic impact of in-stent restenosis in normal weight, overweight, and obese patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(2):260-267.
    View in: PubMed
    Score: 0.167
  40. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
    View in: PubMed
    Score: 0.165
  41. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
    View in: PubMed
    Score: 0.164
  42. Bleeding and Ischemic Risks of Ticagrelor?Monotherapy After Coronary?Interventions. J Am Coll Cardiol. 2023 08 22; 82(8):687-700.
    View in: PubMed
    Score: 0.162
  43. Timing and Predictors of Myocardial Infarction or Stent Thrombosis in High-Bleeding Risk Patients Undergoing PCI. JACC Cardiovasc Interv. 2023 06 26; 16(12):1558-1560.
    View in: PubMed
    Score: 0.161
  44. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. Circulation. 2023 06 20; 147(25):1933-1944.
    View in: PubMed
    Score: 0.161
  45. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023 04 10; 9(3):240-250.
    View in: PubMed
    Score: 0.158
  46. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol. 2023 02 14; 81(6):537-552.
    View in: PubMed
    Score: 0.157
  47. Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease. Catheter Cardiovasc Interv. 2023 02; 101(3):511-519.
    View in: PubMed
    Score: 0.156
  48. New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention. Am J Cardiol. 2023 02 15; 189:22-30.
    View in: PubMed
    Score: 0.155
  49. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
    View in: PubMed
    Score: 0.155
  50. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 10 10; 15(19):1948-1960.
    View in: PubMed
    Score: 0.153
  51. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
    View in: PubMed
    Score: 0.153
  52. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
    View in: PubMed
    Score: 0.153
  53. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022 08 11; 8(5):492-502.
    View in: PubMed
    Score: 0.151
  54. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circ Cardiovasc Interv. 2022 04; 15(4):e009495.
    View in: PubMed
    Score: 0.147
  55. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18; 17(16):1330-1339.
    View in: PubMed
    Score: 0.147
  56. Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Can J Cardiol. 2022 06; 38(6):792-800.
    View in: PubMed
    Score: 0.146
  57. Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. Am J Cardiol. 2022 04 01; 168:47-54.
    View in: PubMed
    Score: 0.146
  58. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
    View in: PubMed
    Score: 0.145
  59. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 12 01; 42(45):4683-4693.
    View in: PubMed
    Score: 0.144
  60. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 12 01; 42(45):4624-4634.
    View in: PubMed
    Score: 0.144
  61. Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC Cardiovasc Interv. 2021 11 22; 14(22):2447-2457.
    View in: PubMed
    Score: 0.144
  62. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021 11 27; 398(10315):1974-1983.
    View in: PubMed
    Score: 0.144
  63. Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. Circ Cardiovasc Interv. 2021 09; 14(9):e010392.
    View in: PubMed
    Score: 0.142
  64. Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheter Cardiovasc Interv. 2021 11 15; 98(6):E785-E795.
    View in: PubMed
    Score: 0.142
  65. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1032-1041.
    View in: PubMed
    Score: 0.142
  66. Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. J Thromb Thrombolysis. 2022 Feb; 53(2):380-389.
    View in: PubMed
    Score: 0.141
  67. Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. J Thromb Thrombolysis. 2022 Jan; 53(1):20-29.
    View in: PubMed
    Score: 0.141
  68. Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention. Eur Heart J. 2021 07 15; 42(27):2710-2711.
    View in: PubMed
    Score: 0.140
  69. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv. 2021 07 12; 14(13):1434-1446.
    View in: PubMed
    Score: 0.140
  70. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 06 16; 373:n1332.
    View in: PubMed
    Score: 0.140
  71. Reply: Percutaneous Coronary Intervention Outcomes According to HbA1c Levels. JACC Cardiovasc Interv. 2021 05 24; 14(10):1159-1160.
    View in: PubMed
    Score: 0.139
  72. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. JAMA Cardiol. 2021 04 01; 6(4):410-419.
    View in: PubMed
    Score: 0.138
  73. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv. 2021 02 22; 14(4):444-456.
    View in: PubMed
    Score: 0.137
  74. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial. Int J Cardiol. 2021 05 01; 330:1-6.
    View in: PubMed
    Score: 0.136
  75. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovasc Drugs Ther. 2021 04; 35(2):309-320.
    View in: PubMed
    Score: 0.136
  76. Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. JACC Cardiovasc Interv. 2020 12 28; 13(24):2882-2892.
    View in: PubMed
    Score: 0.135
  77. A sex paradox in clinical outcomes following complex percutaneous coronary intervention. Int J Cardiol. 2021 04 15; 329:67-73.
    View in: PubMed
    Score: 0.135
  78. Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 06 01; 97(7):E936-E944.
    View in: PubMed
    Score: 0.134
  79. Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 12 15; 137:1-6.
    View in: PubMed
    Score: 0.133
  80. Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. J Am Coll Cardiol. 2020 09 08; 76(10):1274-1275.
    View in: PubMed
    Score: 0.132
  81. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020 Jun 25; 16(3):218-224.
    View in: PubMed
    Score: 0.131
  82. Procedural and 1-year clinical outcomes of orbital atherectomy for treatment of coronary in-stent restenosis: A single-center, retrospective study. Catheter Cardiovasc Interv. 2021 02 15; 97(3):E280-E287.
    View in: PubMed
    Score: 0.130
  83. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol. 2020 06 02; 75(21):2711-2722.
    View in: PubMed
    Score: 0.130
  84. Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Crit Pathw Cardiol. 2020 06; 19(2):69-74.
    View in: PubMed
    Score: 0.130
  85. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 06 01; 116(7):e70-e72.
    View in: PubMed
    Score: 0.130
  86. One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
    View in: PubMed
    Score: 0.130
  87. Impact of renal function on the immediate and long-term outcomes of percutaneous recanalization of coronary chronic total occlusions: A systematic review and meta-analysis. Int J Cardiol. 2020 Oct 15; 317:200-206.
    View in: PubMed
    Score: 0.130
  88. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovasc Revasc Med. 2020 12; 21(12):1542-1547.
    View in: PubMed
    Score: 0.129
  89. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry. Catheter Cardiovasc Interv. 2021 01 01; 97(1):E26-E33.
    View in: PubMed
    Score: 0.129
  90. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.129
  91. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
    View in: PubMed
    Score: 0.129
  92. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 03; 15(18):e1605-e1614.
    View in: PubMed
    Score: 0.128
  93. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 05 19; 75(19):2403-2413.
    View in: PubMed
    Score: 0.128
  94. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020 05 19; 75(19):2414-2424.
    View in: PubMed
    Score: 0.128
  95. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.128
  96. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheter Cardiovasc Interv. 2021 04 01; 97(5):797-804.
    View in: PubMed
    Score: 0.128
  97. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv. 2020 08; 96(2):298-308.
    View in: PubMed
    Score: 0.128
  98. Association between age and readmission after percutaneous coronary intervention for acute myocardial infarction. Heart. 2020 10; 106(20):1595-1603.
    View in: PubMed
    Score: 0.128
  99. Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):E278-E286.
    View in: PubMed
    Score: 0.128
  100. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol. 2020 02 18; 75(6):578-586.
    View in: PubMed
    Score: 0.127
  101. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.127
  102. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. Int J Cardiol. 2020 05 15; 307:17-23.
    View in: PubMed
    Score: 0.127
  103. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
    View in: PubMed
    Score: 0.126
  104. Ventricular Fibrillation Associated With Coronary Plaque Erosion Detected by Optical Coherence Tomography. JACC Cardiovasc Interv. 2020 01 13; 13(1):e5-e7.
    View in: PubMed
    Score: 0.126
  105. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.125
  106. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
    View in: PubMed
    Score: 0.124
  107. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
    View in: PubMed
    Score: 0.123
  108. Feasibility of measuring patient-reported health status at time of percutaneous coronary intervention: Results from a single-center quality-improvement initiative. Eur J Prev Cardiol. 2020 12; 27(19):2183-2186.
    View in: PubMed
    Score: 0.123
  109. Reply: DAPT Cessation and MACE in Elderly Patients: What Is the Optimal Regimen and Duration? JACC Cardiovasc Interv. 2019 08 26; 12(16):1627-1628.
    View in: PubMed
    Score: 0.123
  110. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.123
  111. Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. Curr Opin Cardiol. 2019 07; 34(4):315-322.
    View in: PubMed
    Score: 0.122
  112. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.122
  113. Incidence, determinants and impact of acute kidney injury in patients with diabetes mellitus and multivessel disease undergoing coronary revascularization: Results from the FREEDOM trial. Int J Cardiol. 2019 10 15; 293:197-202.
    View in: PubMed
    Score: 0.122
  114. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 05 27; 12(10):983-992.
    View in: PubMed
    Score: 0.121
  115. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019 05 21; 73(19):2401-2409.
    View in: PubMed
    Score: 0.121
  116. Procedural and one-year outcomes of patients treated with orbital and rotational atherectomy with mechanistic insights from optical coherence tomography. EuroIntervention. 2019 Apr 20; 14(17):1760-1767.
    View in: PubMed
    Score: 0.120
  117. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.120
  118. Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. Int J Cardiol. 2019 07 15; 287:59-61.
    View in: PubMed
    Score: 0.120
  119. Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 15; 123(12):1941-1948.
    View in: PubMed
    Score: 0.120
  120. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 01; 123(11):1788-1795.
    View in: PubMed
    Score: 0.119
  121. Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. Cardiorenal Med. 2019; 9(3):160-167.
    View in: PubMed
    Score: 0.119
  122. Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):E67-E77.
    View in: PubMed
    Score: 0.119
  123. Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
    View in: PubMed
    Score: 0.118
  124. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
    View in: PubMed
    Score: 0.118
  125. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
    View in: PubMed
    Score: 0.118
  126. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019 Jun; 108(6):643-650.
    View in: PubMed
    Score: 0.118
  127. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 12 07; 39(46):4101-4108.
    View in: PubMed
    Score: 0.117
  128. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.117
  129. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019 03 01; 123(5):709-716.
    View in: PubMed
    Score: 0.117
  130. Predictors of side branch compromise in calcified bifurcation lesions treated with orbital atherectomy. Catheter Cardiovasc Interv. 2019 07 01; 94(1):45-52.
    View in: PubMed
    Score: 0.117
  131. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019 Jan 15; 275:31-35.
    View in: PubMed
    Score: 0.116
  132. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.116
  133. Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):825-835.
    View in: PubMed
    Score: 0.116
  134. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2018 Nov; 118(11):1997-2005.
    View in: PubMed
    Score: 0.116
  135. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
    View in: PubMed
    Score: 0.116
  136. Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis. Circ Cardiovasc Interv. 2018 10; 11(10):e006832.
    View in: PubMed
    Score: 0.116
  137. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J. 2019 01; 207:10-18.
    View in: PubMed
    Score: 0.115
  138. Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. Int J Cardiol. 2018 07 15; 263:24-28.
    View in: PubMed
    Score: 0.112
  139. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
    View in: PubMed
    Score: 0.110
  140. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.110
  141. Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin)?±?Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention. Am J Cardiol. 2018 01 15; 121(2):168-176.
    View in: PubMed
    Score: 0.108
  142. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.107
  143. Asymptomatic Large Thrombus Formation in Drug-Eluting Stent 2 Days After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patient. JACC Cardiovasc Interv. 2017 12 11; 10(23):2461-2463.
    View in: PubMed
    Score: 0.107
  144. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.107
  145. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.107
  146. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.106
  147. Mid-term outcomes of consecutive 998 cases of coronary atherectomy in contemporary clinical practice. J Interv Cardiol. 2017 Aug; 30(4):331-337.
    View in: PubMed
    Score: 0.106
  148. Percutaneous Coronary Intervention Outcomes in Very Elderly Patients From a Single Large-Volume Tertiary Care Center, Specifically Focusing on Nonagenarians. JACC Cardiovasc Interv. 2017 06 26; 10(12):1273-1274.
    View in: PubMed
    Score: 0.106
  149. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.105
  150. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.104
  151. Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2017 Feb 20; 12(14):1757-1765.
    View in: PubMed
    Score: 0.104
  152. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.103
  153. Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. Am J Cardiol. 2017 04 15; 119(8):1166-1172.
    View in: PubMed
    Score: 0.103
  154. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. Int J Cardiol. 2017 Mar 01; 230:310-318.
    View in: PubMed
    Score: 0.102
  155. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. J Am Coll Cardiol. 2017 Feb 14; 69(6):628-640.
    View in: PubMed
    Score: 0.101
  156. Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Dec 01; 118(11):1661-1668.
    View in: PubMed
    Score: 0.101
  157. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.101
  158. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.101
  159. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016 Dec 07; 37(46):3440-3447.
    View in: PubMed
    Score: 0.100
  160. Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. J Thromb Thrombolysis. 2016 Aug; 42(2):186-96.
    View in: PubMed
    Score: 0.100
  161. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.099
  162. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.098
  163. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 05 23; 9(10):1036-46.
    View in: PubMed
    Score: 0.098
  164. Resistant in-stent restenosis in the drug eluting stent era. Catheter Cardiovasc Interv. 2016 Nov; 88(5):777-785.
    View in: PubMed
    Score: 0.098
  165. Plaque Morphology Predictors of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions: Optical Coherence Tomography Imaging Study. JACC Cardiovasc Interv. 2016 Apr 25; 9(8):862-865.
    View in: PubMed
    Score: 0.098
  166. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.098
  167. Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):259-268.
    View in: PubMed
    Score: 0.097
  168. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.097
  169. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan; 9(1):e002995.
    View in: PubMed
    Score: 0.096
  170. Efficacy and safety of routine thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2016 Mar; 87(4):650-60.
    View in: PubMed
    Score: 0.095
  171. Meta-Analysis of Radial Versus Femoral Access for Percutaneous Coronary Interventions in Non-ST-Segment Elevation Acute Coronary Syndrome. Am J Cardiol. 2016 Jan 15; 117(2):172-8.
    View in: PubMed
    Score: 0.095
  172. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015 Dec; 170(6):1234-42.
    View in: PubMed
    Score: 0.094
  173. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015 Aug; 8(8):e002475.
    View in: PubMed
    Score: 0.093
  174. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016 Jan; 171(1):40-7.
    View in: PubMed
    Score: 0.093
  175. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.092
  176. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015 Jun; 8(7):937-45.
    View in: PubMed
    Score: 0.092
  177. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015 Jul 01; 116(1):37-42.
    View in: PubMed
    Score: 0.091
  178. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol. 2014 Jun; 62(3):261-76.
    View in: PubMed
    Score: 0.086
  179. Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. Int J Cardiol. 2014 Jun 01; 174(1):13-7.
    View in: PubMed
    Score: 0.084
  180. Impact of major bleeding on long-term mortality in anemic versus nonanemic patients undergoing percutaneous coronary intervention using bivalirudin. Am J Cardiol. 2014 May 01; 113(9):1481-6.
    View in: PubMed
    Score: 0.084
  181. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.081
  182. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.080
  183. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012 Dec; 5(12):1231-8.
    View in: PubMed
    Score: 0.077
  184. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2012 Oct 01; 80(4):514-21.
    View in: PubMed
    Score: 0.072
  185. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23; 150(4):317-335.
    View in: PubMed
    Score: 0.043
  186. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.029
  187. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
    View in: PubMed
    Score: 0.027
  188. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Int J Cardiol. 2017 Nov 01; 246:20-25.
    View in: PubMed
    Score: 0.027
  189. Increased Lipid Length, Macrophage Infiltration, and Neovascularization in Coronary Atheroma From Patients With Chronic Kidney Disease. JACC Cardiovasc Imaging. 2017 12; 10(12):1524-1526.
    View in: PubMed
    Score: 0.026
  190. Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc. 2016 11 19; 5(11).
    View in: PubMed
    Score: 0.025
  191. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.024
  192. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015 Apr 07; 65(13):1298-1310.
    View in: PubMed
    Score: 0.022
  193. Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? Curr Opin Cardiol. 2014 Jul; 29(4):301-6.
    View in: PubMed
    Score: 0.022
  194. An allele-specific PCR system for rapid detection and discrimination of the CYP2C19*4A, *4B, and *17 alleles: implications for clopidogrel response testing. J Mol Diagn. 2013 Nov; 15(6):783-9.
    View in: PubMed
    Score: 0.020
  195. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 07; 382(9908):1879-88.
    View in: PubMed
    Score: 0.020
  196. Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2014 Feb; 15(2):201-9.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES